<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131468</url>
  </required_header>
  <id_info>
    <org_study_id>OTOTOXICITY RESEARCH IN PD</org_study_id>
    <nct_id>NCT01131468</nct_id>
  </id_info>
  <brief_title>Prevention of Drug Induced Ototoxicity in Peritoneal Dialysis Patients by N-Acetylcysteine</brief_title>
  <official_title>The Evaluation of the Protective Effect of N-Acetylcysteine Against Drug Induced Ototoxicity in Peritoneal Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TC Erciyes University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TC Erciyes University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether N-acetylcysteine is effective in the
      prevention of hearing loss in both ears due to aminoglycoside and/or vancomycine induced
      ototoxicity in peritoneal dialysis patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Drug-induced Ototoxicity in Peritoneal Dialysis Patients</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-acetylcysteine 600 mg twice daily + vancomycine and/or amikacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Vancomycine and/or amikacin alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>N-acetylcysteine 600 mg twice daily or vancomycine+amikacin alone</description>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  End-stage renal disease

          -  Undergoing continuous ambulatory peritoneal dialysis as a renal replacement therapy

          -  Clinical diagnosis of a peritonitis episode in a continuous ambulatory peritoneal
             dialysis patient

          -  Developing the first continuous ambulatory peritoneal dialysis related peritonitis
             episode

        Exclusion Criteria:

          -  Being treated with aminoglycoside antibiotics and vancomycine within the previous 3
             months

          -  Detection of mechanical occlusion of external ear

          -  Having signs of disturbed integrity of tympanic membrane on otoscopy or tympanometry

          -  History of a continuous ambulatory peritoneal dialysis related peritonitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bulent Tokgoz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erciyes University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erciyes University School of Medicine Department of Nephrology</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2010</study_first_posted>
  <last_update_submitted>May 26, 2010</last_update_submitted>
  <last_update_submitted_qc>May 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2010</last_update_posted>
  <keyword>ototoxicity</keyword>
  <keyword>aminoglycoside</keyword>
  <keyword>vancomycine</keyword>
  <keyword>peritoneal dialysis</keyword>
  <keyword>peritonitis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>Amikacin</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

